We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AZ’s Brilinta Approved With Boxed Warning, REMS
AZ’s Brilinta Approved With Boxed Warning, REMS
July 22, 2011
The FDA has approved AstraZeneca’s blood-thinner Brilinta and is requiring a boxed warning and risk evaluation and mitigation strategy (REMS) for the product because concomitant higher doses of aspirin diminish its effectiveness.